The $5 Billion Hop: Glatiramer Acetate and the US Patent System.

New research and a government investigation have shed light on an anticompetitive practice called "Product Hopping" and specifically how it was employed in the case of the multiple sclerosis treatment glatiramer acetate beginning in 2014, which cost payers billions of dollars. We examine this case as well as a separate, impending instance of product hopping. [ABSTRACT FROM AUTHOR]